- Home
- ALKS
ALKS
Alkermes plc
as 07-25-2025 4:00pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Upcoming Earnings Alert:
Get ready for potential market movements as Alkermes plc ALKS prepares to release earnings report on 29 Jul 2025.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 5.1B | IPO Year: | 1991 |
| Target Price: | $40.23 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.09 | EPS Growth: | -17.49 |
| 52 Week Low/High: | $25.56 - $36.45 | Next Earning Date: | 07-29-2025 |
| Revenue: | $1,513,770,000 | Revenue Growth: | -12.30% |
| Revenue Growth (this year): | -9.35% | Revenue Growth (next year): | 4.18% |
Stock Insider Trading Activity of Alkermes plc (ALKS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nichols Christian Todd | ALKS | SVP, Chief Commercial Officer | Jun 9 '25 | Sell | $31.52 | 6,667 | $210,143.41 | 89,542 |
Latest Alkermes plc News
ALKS Breaking Stock News: Dive into ALKS Ticker-Specific Updates for Smart Investing
TipRanks
a month ago
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls
MT Newswires
a month ago
Alkermes' ALKS-2680 Seen as Potential Breakthrough for Narcolepsy, Hypersomnia, BofA Says
MT Newswires
a month ago
UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33
Zacks
2 months ago
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
PR Newswire
2 months ago
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
PR Newswire
2 months ago
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
Simply Wall St.
2 months ago
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 49% Undervaluation?
PR Newswire
2 months ago
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
Compare ALKS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.